A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)

  • Glaspole, Ian (Primary Chief Investigator (PCI))
  • Symons, Karen M. (Project Manager)

Project: Research

Project Details

StatusActive
Effective start/end date23/06/20 → 31/12/22
View all
View less

Keywords

  • Respiratory medicine
  • Idiopathic pulmonary fibrosis
  • Clinical trial